XML 14 R4.htm IDEA: XBRL DOCUMENT v3.21.2
CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Development revenues:        
Government contracts and other       $ 303
Operating expenses:        
Research and development $ 1,491 $ 336 $ 3,724 1,604
General and administrative 1,990 1,060 4,811 4,107
Loss on disposal of property and equipment 18   18 0
Total operating expenses 3,499 1,396 8,553 6,492
Loss from operations (3,499) (1,396) (8,553) (6,189)
Other income (expense):        
Interest income 5 2 13 47
Interest expense (232) (253) (708) (854)
Change in fair value of warrants 2 (81) 4 2,342
Total other income (expense) (225) (332) (691) 1,535
Net loss $ (3,724) $ (1,728) $ (9,244) $ (4,654)
Net loss per share, basic and diluted $ (0.28) $ (0.39) $ (0.84) $ (1.13)
Basic and diluted weighted average shares used in calculating net loss per share attributable to common stockholders 13,264,230 4,402,221 10,961,284 4,113,928
In Process Research and Development [Member] | Nano Tx Therapeutics [Member]        
Operating expenses:        
Research and development       $ 781